CPIX.NASDAQCumberland Pharmaceuticals INC

Form 4: Cumberland Pharma CEO Boosts Stake in Company

Sentiment:

Insider Transaction Report

📋All filings for Cumberland Pharmaceuticals INC
🔒Login to Follow

Cumberland Pharmaceuticals' Chairman and CEO, A.J. Kazimi, acquired additional common stock through a pre-arranged 10b5-1 trading plan in November 2025.

Summary

  • A.J. Kazimi, Chairman and CEO, and a 10% owner of Cumberland Pharmaceuticals Inc. (CPIX), acquired additional shares of common stock.
  • The transactions occurred between November 3, 2025, and November 28, 2025.
  • A total of 295 shares were acquired across 19 separate transactions.
  • The purchase prices ranged from $1.96 to $2.82 per share.
  • All purchases were made directly by Mr. Kazimi.
  • Following these transactions, Mr. Kazimi beneficially owns 5,700,885 shares of common stock.
  • These purchases were executed automatically pursuant to a Rule 10b5-1 trading plan adopted by Mr. Kazimi on November 14, 2024.

Sentiment

Score: 8

Explanation: The consistent acquisition of common stock by the Chairman and CEO, who is also a 10% owner, indicates strong insider confidence in the company's valuation and future prospects. This is generally viewed as a positive signal by the market.

Positives

  • Consistent insider buying by the Chairman and CEO signals strong confidence in the company's future prospects and valuation.
  • The purchases were made through a Rule 10b5-1 plan, indicating a pre-planned investment strategy rather than a reaction to immediate market events.

Related Party Transactions

  • A.J. Kazimi, Chairman and CEO, and a 10% owner of Cumberland Pharmaceuticals Inc., acquired common stock directly.

Stakeholder Impact

  • Shareholders may view the insider buying as a positive indicator of management's belief in the company's value, potentially boosting investor confidence.

Key Dates

DateDescription
11/14/2024Date Rule 10b5-1 trading plan was adopted by A.J. Kazimi.
11/03/2025First transaction date for common stock acquisition.
11/04/2025Transaction date for common stock acquisition.
11/05/2025Transaction date for common stock acquisition.
11/06/2025Transaction date for common stock acquisition.
11/07/2025Transaction date for common stock acquisition.
11/10/2025Transaction date for common stock acquisition.
11/11/2025Transaction date for common stock acquisition.
11/12/2025Transaction date for common stock acquisition.
11/13/2025Transaction date for common stock acquisition.
11/14/2025Transaction date for common stock acquisition.
11/17/2025Transaction date for common stock acquisition.
11/18/2025Transaction date for common stock acquisition.
11/19/2025Transaction date for common stock acquisition.
11/20/2025Transaction date for common stock acquisition.
11/21/2025Transaction date for common stock acquisition.
11/24/2025Transaction date for common stock acquisition.
11/25/2025Transaction date for common stock acquisition.
11/26/2025Transaction date for common stock acquisition.
11/28/2025Last transaction date for common stock acquisition.
12/01/2025Signature date of the reporting person's attorney-in-fact.

Recommendation

buy

The consistent and direct purchases of common stock by the Chairman and CEO, who is also a significant 10% owner, through a pre-arranged 10b5-1 plan, signals strong conviction in the company's intrinsic value and future performance. Such insider buying often precedes positive developments or indicates that management believes the stock is undervalued, making it a favorable signal for potential investors.

Keywords

Cumberland Pharmaceuticals, CPIX, A.J. Kazimi, Insider Trading, Stock Purchase, 10b5-1 Plan, Common Stock, Executive Ownership

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.